Abstract
Aims: To evaluate the clinical efficacy of Human Urinary Kallidinogenase (HUK) and Maixuekang capsule in the treatment of acute ischemic stroke (AIS) patients.Methods: In this study, from January 2016 to July 2016, 60 patients with acute ischemic stroke were enrolled and 56 patients with complete information of whom 21 patients received HUK+ basic treatment (HUK group), 16 patients received HUK+ Maixuekang capsule + basic treatment (HUK+ Maixuekang group), 19 patients received basic treatment (control group). 0.15 PNA unit of HUK injection plus 100 ml saline in intravenous infusion was performed in the HUK group and HUK+ Maixuekang group, with once a day for 14 consecutive days. 0.75 g Maixuekang capsules were taken in HUK+ Maixuekang group, with three times a day for 14 consecutive days. The National Institutes of Health Stroke Scale (NIHSS) scores in three groups were analyzed 7 days after treatment. The modified Rankin Scale (mRS) scores in three groups were analyzed 12 month after the treatment.Results: No difference was found in the NIHSS scores, age, gender, and comorbidities between three groups before treatment (p > 0.05). Seven days after treatment, the NIHSS scores in the HUK group and HUK+ Maixuekang group were significantly decreased than before (p HUK = 0.001, p HUK+Maixuekang < 0.001), and lower than that in the control group (p HUK = 0.032; p HUK+Maixuekang < 0.001). Twelve months after treatment, good functional outcome rate (12 month mRS score ≤ 2) in the HUK group and HUK+ Maixuekang group was significantly higher than that in the control group (p HUK = 0.049, p HUK+Maixuekang = 0.032).Conclusion: The treatment of HUK or HUK combined with Maixuekang capsule can effectively improve the neurological function and promote long-term recovery for AIS patients.
Highlights
Stoke is the second most common cause of death and the leading cause of adult disability worldwide (Bonita et al, 2004)
The treatment of human urinary kallidinogenase (HUK) or HUK combined with Maixuekang capsule can effectively improve the neurological function and promote long-term recovery for acute ischemic stroke (AIS) patients
There were 14 males and 7 females in the HUK group, with an average age at 58.10 ± 13.66 years old and the National Institutes of Health Stroke Scale (NIHSS) score of this before treatment was 5.19 ± 1.60; There were 11 males and 5 females in the HUK + Maixuekang group, with an average age at 60.88 ± 11.85 years old and the NIHSS score of this before treatment was 5.12 ± 1.75; There were 13 males and 6 females in the control group, with an average age at 61.1 ± 14.46 years old and the NIHSS score of this before treatment was 5.21 ± 1.69; There was no significant difference between these three groups in age, gender, NIHSS score, CHA2DS2−VASc score, C reactive protein (CRP) level before treatment and echocardiographic parameters (p > 0.05)
Summary
Stoke is the second most common cause of death and the leading cause of adult disability worldwide (Bonita et al, 2004). The clinically-validated treatment for stroke available is acute thrombolysis, and the utility of this approach is constrained by the need to initiate treatment within 4.5 h of symptoms and the risk of causing cerebral hemorrhage. These factors have limited the number of stroke patients receiving this treatment to
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call